Effects of glucose and blood pressure control
on complications of type 2 diabetes mellitus

C.E. Nasr, B.J. Hoogwerf, C. Faiman, and S.S.K. Reddy

Abstract

The United Kingdom Prospective Diabetes Study (UKPDS) showed that intensive treatment (ie, glucose-lowering drugs, with a goal fasting blood glucose level of 108 mg/dL) decreases the microvascular complications of type 2 diabetes mellitus. We summarize the key study results and their implications for clinical management of type 2 diabetes mellitus.

Authors

Christian E. Nasr, MD, Department of Endocrinology and Metabolism, Cleveland Clinic

Byron J. Hoogwerf, MD, Department of Endocrinology and Metabolism, Cleveland Clinic

Charles Faiman, MD, Chairman, Department of Endocrinology and Metabolism, Cleveland Clinic

S. Sethu K. Reddy, MD, Department of Endocrinology and Metabolism, Cleveland Clinic

Address: S. Sethu K. Reddy, MD, Department of Endocrinology, A30, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195.

John D. Clough, M.D., editor-in-chief
Linda K. Hengstler, editor and publisher
Phillip E. Canuto, executive editor
Ray Borazanian, managing editor

The Cleveland Clinic Foundation
Cleveland Clinic Journal of Medicine, NA32
9500 Euclid Avenue
Cleveland, Ohio 44195

216.444.2661, FAX 216.444.9385, ccjm@ccf.org

This page maintained by the Division of Education, education@ccf.org. 4/99